The short answer

The latest cancer exercise meta-analysis identified 21 randomized controlled trials of structured exercise in adults with confirmed cancer. Across the trials that reported each outcome, structured exercise was associated with better overall survival, disease-free survival, all-cause mortality, and cancer-specific mortality.

That is encouraging, but it needs careful interpretation:

• The 21 trials are the full evidence base in this review. Not every trial contributed to every outcome.
• Pooled findings do not mean that exercise produces the same effect for every cancer type, stage, treatment setting, age group, or level of fitness.
• Exercise is an adjunct to indicated cancer care. It does not replace surgery, chemotherapy, radiotherapy, immunotherapy, endocrine therapy, or other treatments.
• The clearest large randomized example is a three-year, behaviorally supported program for a specific group, people with resected stage II or III colon cancer who had completed adjuvant chemotherapy.

What the 21 randomized trials found

The review pooled different subsets of trials according to which survival outcome they reported.

For overall survival and disease-free survival, the review rated the certainty of evidence as moderate. These pooled estimates are associations across the included randomized comparisons, not a guarantee of an identical benefit for an individual person.

Disease-free survival is not automatically recurrence alone

The disease-free-survival finding is relevant to searches for exercise cancer recurrence, but it should not be simplified into a claim that exercise independently prevents recurrence in every setting. Disease-free survival can combine recurrence, new primary cancers, and death in different ways across trials. The exact endpoint definition matters.

A landmark example: the CHALLENGE colon cancer trial

The 2025 CHALLENGE trial provides particularly direct randomized evidence in a defined clinical setting. It enrolled 889 people with resected stage II or III colon cancer after they had completed adjuvant chemotherapy.

Participants were assigned to a three-year structured exercise program or health-education materials. At a median follow-up of 7.9 years, the exercise group had better disease-free survival, with an HR of 0.72, 95% CI 0.55 to 0.94. The trial also reported a favorable overall-survival result, HR 0.63, 95% CI 0.43 to 0.94.

This trial is important because it was large, phase 3, randomized, and had long follow-up. It also illustrates why the details matter. Its findings apply most directly to its studied population, not automatically to metastatic disease, other cancer types, or people unable to take part in a similarly supported program. This was more than a simple unsupervised recommendation to walk. It included substantial behavioral support over three years.

Which kinds of exercise were studied?

The randomized evidence includes different exercise categories:

• Aerobic exercise
• Combined aerobic and resistance training
• Resistance training alone

Earlier randomized research included breast, lung, hematologic, and mixed cancer populations, with programs delivered at varying points around treatment and using aerobic, resistance, or combined approaches. That diversity helps explain why a single pooled number cannot answer every patient's question about exercise cancer survival.

Aerobic exercise and adherence

Exploratory analyses in the 2026 review suggested more pronounced effects among participants with higher adherence, aerobic-exercise interventions, and early-stage disease groups.

These are signals worth studying, not proof that aerobic exercise is universally superior. Subgroup results may be influenced by differences among the trials, including cancer type, stage, program duration, support, adherence, and the number of events. They may also be underpowered or affected by multiple comparisons.

The practical takeaway is not that everyone should follow a single aerobic program. It is that sustained participation in a structured, feasible program may matter, and that behavioral support may be part of what makes an intervention workable.

Combined aerobic and resistance training

Combined programs are a distinct category, rather than simply a weaker or stronger version of aerobic exercise. They may address more than one goal, but the available pooled survival evidence does not establish a definitive modality ranking across all cancers and treatment settings.

For patients and clinicians, the right program must still account for diagnosis, stage, treatment effects, symptoms, health status, and functional capacity.

Resistance training cancer: why a non-significant survival result is not a verdict

A statistically non-significant survival finding for resistance training alone should not be interpreted as evidence that resistance training is ineffective or unimportant. Fewer resistance-only studies may report survival outcomes, and a survival subgroup analysis does not capture every clinically meaningful outcome.

Authoritative cancer guidance reports strong evidence that moderate-intensity aerobic training and/or resistance exercise during and after treatment can improve physical function and health-related quality of life, and reduce fatigue, anxiety, and depressive symptoms. Resistance training cancer programs can therefore remain highly relevant for strength, lean mass, physical function, fatigue, and quality of life, even when survival estimates alone are uncertain.

Why the pooled results cannot apply equally to everyone

The trials combined in this review differed in major ways that can affect outcomes and interpretation:

• Cancer biology and cancer type
• Disease stage, including early-stage populations and other settings
• Treatment timing, including during treatment or after treatment
• Baseline fitness and functional status
• Exercise modality, dose, duration, supervision, and behavioral support
• Adherence to the assigned program
• Comparator activity or health-education support
• Definitions of outcomes, particularly disease-free survival
• Follow-up duration, event counts, and underlying prognosis

These differences are called heterogeneity. They do not erase the favorable pooled findings, but they limit how precisely those findings can be applied to an individual.

This is also why observational evidence should not be treated as interchangeable with randomized evidence. People who are healthier, less frail, or better able to access care may also be more able to exercise. Randomized trials are designed to reduce that problem, but even randomized trial results remain specific to the people, interventions, and settings studied.

What this means for exercise during and after cancer treatment

The evidence supports discussing structured exercise as part of supportive and survivorship care. The 21-trial analysis suggests potential survival relevance, and the CHALLENGE trial shows a favorable result in one well-defined colon cancer setting. But exercise should be added to, not substituted for, standard oncology treatment.

An exercise plan should be individualized with the oncology team, particularly during active treatment or when anemia, thrombocytopenia, infection risk, cardiopulmonary disease, neuropathy, severe symptoms, or bone metastases are present. The National Cancer Institute similarly emphasizes tailoring exercise to the person's cancer, treatment, symptoms, and health status.

Rather than asking whether one exercise mode is “best” for all people with cancer, more useful questions include:

• What type of movement is safe and feasible right now?
• Is aerobic training, resistance training, or a combined program most aligned with current goals and limitations?
• What support could help sustain adherence?
• How should the plan change with treatment, symptoms, or functional changes?

Bottom line

Current randomized evidence offers a cautious but meaningful answer to the question of exercise cancer survival. In a review of 21 trials, structured exercise was associated with favorable pooled survival and mortality outcomes, although each endpoint came from a smaller subset of studies. A large phase 3 trial also found improved disease-free survival after adjuvant chemotherapy in people with resected stage II or III colon cancer.

The results are promising, not universal. Exercise may be a valuable component of cancer care, especially when structured, supported, and tailored, but it is not a replacement for anticancer treatment. Aerobic exercise showed an exploratory survival signal, while resistance training remains valuable for physical and quality-of-life outcomes regardless of whether resistance-only survival analyses reach statistical significance.